Details

Autor(en) / Beteiligte

• Schubert, Peter
• Culibrk, Brankica
• Bhakta, Varsha
• Closas, Tatiana
• Sheffield, William P.
• Devine, Dana V.
• McTaggart, Ken

Titel

Minimal impact of anticoagulant on in vitro whole blood quality throughout a 35‐day cold‐storage regardless of leukoreduction timing

Ist Teil von

• Transfusion (Philadelphia, Pa.), 2022-08, Vol.62 (S1), p.S98-S104

Ort / Verlag

Hoboken, USA: John Wiley & Sons, Inc

Erscheinungsjahr

2022

Quelle

Wiley-Blackwell Journals

Beschreibungen/Notizen

• Background There is increasing interest in leukoreduced whole blood (WB) as a transfusion product for trauma patients. In some jurisdictions, few leukoreduced filters are approved or appropriate for WB leukoreduction and quality information is therefore limited. This study assessed the impact of filtration timing of WB collected in CPDA‐1 versus CPD on in vitro quality. Study Design and methods WB was collected in CPDA‐1 or CPD and leukoreduction filtered either after 3–8 h (early) or 18–24 h (late) from stop bleed time. In vitro quality was assessed after filtration and throughout 5 weeks of storage at 4°C. Cell count and hemoglobin levels were determined by hematology analyzer, platelet activation and responsiveness to ADP by surface expression of P‐selectin by flow cytometry, hemolysis by HemoCue, and metabolic parameters by blood gas analyzer. Hemostatic properties were assessed by rotational thromboelastometry. Plasma protein activities and clotting times were determined by automated coagulation. Results Although there were some data points which showed statistically significant differences associated with anticoagulant choices or the filtration timing, no general trend in inferiority/performance could be discerned. After 35 days' storage, only clotting time, alpha angle and factor II in the early filtration arm comparing anticoagulants and prothrombin time and factor II in the CPDA‐1 study arm comparing filtration timing showed a significant difference. Conclusion In vitro WB quality seems to be independent on the choice of anticoagulant and filtration timing supporting WB hold‐times to up to 24 h, increasing operational flexibility for transfusion services.